Medical Devices Startups

Virtual Vision develops an FDA-registered Virtual Eye device for eyecare professionals to diagnose and manage ocular conditions using advanced testing solutions. The company is backed by research conducted at Bascom Palmer Eye Institute.

1 investor

Virtue Health (operating as The Home Hospital) builds an operating model and platform for distributed hospital infrastructure, aiming to deliver specialist-led hospital care in patients' homes through virtual wards. It targets healthcare providers such as the NHS in the United Kingdom.

1 investor

Virtuoso Therapeutics is an oncology-focused biotech developing novel bispecific antibody therapies aimed at addressing challenges like efficacy and therapeutic window. It operates a hybrid US-China model for virtual R&D, drawing on science and talent from both regions.

1 investor

Virtus Medical provides comprehensive personal health management services across preventative care, diagnosis, treatment, and rehabilitation for patients of various ages and health conditions, leveraging Hong Kong's medical expertise and Macau's medical tourism facilities to serve the Greater Bay Area and major Chinese cities.

1 investor

Visano Theranostics develops PSMA-targeted nanobubble contrast agents that add real-time molecular imaging to standard ultrasound workflows for the diagnosis and treatment of prostate cancer. The company licensed nanobubble technologies from Case Western Reserve University and is focused on precision oncology for prostate cancer.

1 investor

Vision Ease manufactures vision care products and operates its Ramsey, Minnesota facility using 100 percent renewable energy with a 99 percent reduction in carbon emissions achieved through energy efficiency, sustainable packaging, and waste recycling measures.

1 investor

Vision Innovation Partners provides management and operational support services to ophthalmology and eye care practices in the Mid-Atlantic region, handling practice management, compliance, finance, and marketing functions. The company enables independent eye care practitioners to focus on clinical work while delegating business operations.

1 investor

VistaApex Solutions provides dental equipment and supplies focused on endodontics, including devices and materials designed to improve root canal treatment outcomes for dental clinicians.

1 investor

Vistapath develops the Sentinel platform, an AI-powered system for automated tissue grossing used in pathology laboratories. It serves clinical and diagnostic labs to support pathology digitization, precision, and workflow efficiency.

1 investor

Vistel (致远慧图) develops AI-based screening and evaluation tools for blinding eye diseases such as diabetic retinopathy, glaucoma, macular degeneration, and vein occlusion, along with intelligent ophthalmic imaging management, telemedicine, and myopia prevention systems. It serves hospitals and ophthalmology providers in China with AI-powered medical imaging analysis.

1 investor

VISUS ONE operates eye clinics offering laser refractive surgery and lens implantation procedures to correct vision disorders. The clinics are located in Düsseldorf and Cologne, Germany, and use ZEISS technology for precision eye treatments.

1 investor

Vita Innovations develops an AI-powered triage platform for emergency departments that automates patient intake, improves clinical decision-making, and helps manage capacity constraints in hospital settings.

1 investor

Vitala provides a digital platform and care model that enables healthcare organizations to prescribe, monitor, and deliver structured exercise and lifestyle programs to patients managing chronic disease, cancer, rehabilitation, and other conditions. The company serves healthcare providers and clinical programs seeking to measure and scale lifestyle interventions as part of standard clinical care.

1 investor

Vital Care operates a franchise network of locally owned infusion pharmacies that deliver chronic and acute infusion therapies to patients in home and alternate care settings. The company serves patients requiring infusion treatments and healthcare providers seeking alternative delivery models to hospital-based care.

1 investor

The BARDA Accelerator Network fosters health security innovation ecosystems worldwide and accelerates development and commercialization of next-generation health security solutions. It is established by the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services.

1 investor

A pharmaceutical company that develops and manufactures injectable medications across therapeutic areas including infectious disease, cardiology, anesthesia, gastroenterology, neurology, and oncology, as well as ophthalmic solutions and semi-solid products.

1 investor

VitalPath designs and manufactures complex catheters and precision laser components for medical device OEMs, offering rapid prototyping and full-scale production in ISO-certified cleanroom facilities. The company serves customers across cardiology, neurology, and peripheral vascular markets with vertically integrated capabilities from design through finished device assembly.

1 investor

VitalSigns develops a smart diagnostic device that captures and analyzes multiple bio-signals simultaneously for primary care, home monitoring, and telemedicine applications. The company combines hardware and AI to support clinical decision-making in primary care and nursing settings across Europe.

1 investor

Vitalthings develops contactless, camera-free monitoring devices that continuously measure vital signs, sleep, and patient presence for use in hospitals, care institutions, and home care. Its products (Guardian H10, M10, View, and Somnofy) serve healthcare personnel and patients, with a stated focus on Norway and Germany.

1 investor

VitalWear develops wearable technology using advanced fiber materials. The company is in pre-seed stage and targets applications in health monitoring and sensing.

1 investor

Viva In Vitro Diagnostics is a biotech company that researches and develops diagnostic solutions and services focused on the NLRP3 inflammasome and inflammatory processes, including biomarkers for early prognosis and patient stratification in sepsis. A spin-off of Murcia's biomedical research institute (IMIB), it serves hospitals, laboratories, and research centers, with its own lab in the Parque Científico de Murcia, Spain.

1 investor

Vivacelle Bio develops phospholipid nanoparticle therapies (VBI-S and VBI-1) that restore intravascular volume and redirect excess nitric oxide to treat hypovolemia in patients with septic shock or severe blood loss. The company is running a Phase III trial for its lead asset VBI-S in septic shock patients across U.S. sites.

1 investor

Vivaldi Biosciences develops Delta NS1 vaccines designed to protect against epidemic and pandemic viral respiratory diseases. The company operates research operations in Colorado and Austria.

1 investor

Vivalyx develops organ revitalization technology aimed at improving organ vitality for transplantation. The company works in the medical biotechnology field.

1 investor